Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma

Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma

The use of immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 and CTLA-4 has transformed the oncology practice of hepatocellular carcinoma. However, only 25–30% of the patients with advanced HCC treated with atezolizumab-bevacizumab or tremelimumab-durvalumab (STRIDE) respond initially, and me...

Full description

Saved in:
Bibliographic Details
Main Authors: Benjamin Koh, Darren Jun Hao Tan, Wen Hui Lim, Jeffrey S L Wong, Cheng Han Ng, Kai En Chan, Meng Wang, Wei Peng Yong, Yock Young Dan, Louis Z Wang, Nigel Tan, Mark Muthiah, Alfred Kow, Nicholas L. Syn, Daniel Q. Huang, Thomas Yau
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
Hepatocellular carcinoma
immune checkpoint blockade
Neoadjuvant immunotherapy
precision immunotherapy
transplant oncology
tumor microenvironment
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2214478
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2023.2214478

Similar Items